Brief: Galmed Reports Interim Results From The Armor Study With Aramchol

Eocene

28/04/2022 12:57

April 28 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED REPORTS INTERIM RESULTS FROM THE OPEN-LABEL PART OF
THE
ARMOR STUDY WITH ARAMCHOL SHOWING ROBUST FIBROSIS IMPROVEMENT
ACROSS MULTIMODALITY HISTOLOGICAL ASSESSMENT
    * GALMED - AT WEEK 48, BOTH PAIRED AND AI EVALUATIONS
IDENTIFIED
MORE SUBJECTS WITH FIBROSIS IMPROVEMENT COMPARED TO NASH CRN
SCORING

Source text for Eikon:  ID:nPn7bBg1va 
Further company coverage:  GLMD.O 

 ((reuters.briefs@thomsonreuters.com;))